Abstract: A method of evaluating an action includes (1) obtaining a first stem-cell data related to a subject before performing the action, (2) performing the action on the subject, (3) obtaining a second stem-cell data related to the subject after performing the action, and (4) identifying the effect of the action on the subject based on the first stem-cell data and the second stem-cell data. The subject may be a human or an animal. The action may be taking a drug or taking a nutrient or dietary supplement, which may include fucoidan. Each of the first and second stem-cell data may include the count of a type or types of stem cells and/or the percentage of the type or types of stem cells and may be obtained by the same method including counting cells using a cell counter or cell counting device such as flow cytometer.

Abstract: The present disclosure relates to a prosthesis for dental replacement, the prosthesis includes a root. The root includes an abutment and a base portion. The abutment is adapted for affixation of a dental crown thereto. The base portion is shaped for insertion into a tooth socket. The base portion includes a core, a metallic oxide layer on the core and a film-like stem cell layer on the metallic oxide layer. The metallic oxide layer has a number of holes.

Abstract: Disclosed are methods of using blastomere-like stem cells to decrease a level of myeloid-derived suppressor cells (MDSCs). A method for decreasing a level of myeloid-derived suppressor cells (MDSCs) in a human subject, including: injectionally, orally or transdermally administering to the human subject an amount of human blastomere-like stem cells, autologous to the human subject, at 1×108 to 1×1011 cells each time once every two weeks, for example.

Abstract: Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Abstract: Provided herein are methods of treating cancer in a subject, by administering COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide)). The methods of treating include treating a BRCA1-defective subject, a PARP1 inhibitor-resistant subject or a DNA-damaging anti-cancer agent resistant subject. The methods include treating cancer by administering COH29 and a DNA-damaging anti-cancer agent in a combined synergistic amount.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclilaxei and its derivatives, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: A method for survival prediction in cancer patients is provided. In one embodiment, the survival prediction is determined by the presence or absence of KRAS gene region deletion and/or loss of Chromosome 12 (Ch. 12) in cancer tumor tissue. In another embodiment, the presence or absence of KRAS gene region deletion and/or loss of Ch. 12 in cancer tumor tissue is used to predict survival in non-small-cell lung cancer (NSCLC) patients.

Abstract: The present invention provides a method for detecting transplantation failure of a transplanted organ or cells which comprises detecting a donor-positive but recipient-negative DNA marker in the recipient's plasma using pyrophosphorolysis activated polymerization. Because of the high sensitivity, specificity and selectivity of pyrophosphorolysis activated polymerization, transplantation failure can be detected at early stages and treatment can be initiate earlier.

Abstract: A method of obtaining stem cells includes (1) a subject (such as a human or an animal) taking or being subjected to an action, (2) after the subject taking or being subject to the action, the subject waiting for a predetermined time interval (such as between 30 minutes and 2 hours), (3) after the subject waiting for the predetermined time interval, taking a tissue sample (such as a peripheral blood of the subject) from the subject, and (4) collecting the stem cells from the tissue sample. The step of the subject taking or being subjected to the action may include the subject taking a herb medicine or an object containing fucoidan. The stem cells may be configured for a dental implant surgery. The stem cells may include a CD9(+), CD349(+) cell between 0.1 and 6.0 micrometers in size and/or a Lgr5(+) cell between 0.1 and 6.0 micrometers in size.

Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.

Abstract: Next generation sequencing technologies are becoming a preferred method for sequencing nucleic acids and profiling miRNAs. Experimental results disclosed herein show that the most common platform for preparing nucleic acids such as miRNAs for sequencing introduces serious biases. Provided herein are compositions and methods for improved sequencing and miRNA profiling using a set of customized ligation adaptors.

Abstract: A method of evaluating an action includes (1) obtaining a first stem-cell data related to a subject before performing the action, (2) performing the action on the subject, (3) obtaining a second stem-cell data related to the subject after performing the action, and (4) identifying the effect of the action on the subject based on the first stem-cell data and the second stem-cell data. The subject may be a human or an animal. The action may be taking a drug or taking a nutrient or dietary supplement, which may include fucoidan. Each of the first and second stem-cell data may include the count of a type or types of stem cells and/or the percentage of the type or types of stem cells and may be obtained by the same method including counting cells using a cell counter or cell counting device such as flow cytometer.

Abstract: Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders.

Abstract: Disclosed are methods of using blastomere-like stem cells to (1) decrease the level of myeloid-derived suppressor cells, (2) modulate immune response, (3) overcome a myeloid-derived suppressor cell-mediated immunosuppression, and (4) treat a cellular proliferative disorder. The blastomere-like stem cells, positive for CD66e, can be isolated from blood, bone marrow, or skeletal muscle.

Abstract: Disclosed are novel stem cells of non-embryonic origins and the uses thereof.

Abstract: Methods for identifying or classifying a gene mutation type associated with acquired drug resistance of cancer is provided. Said methods may include determining a total copy number (N) of a susceptible gene in a cancer cell, identifying a mutant copy number of the susceptible gene, determining a mutant copy number sufficient to cause acquired drug resistance (M); and comparing N with M to identify or classify the mutation type in the cancer cell.

Abstract: Next generation sequencing technologies are becoming a preferred method for sequencing nucleic acids and profiling miRNAs. Experimental results disclosed herein show that the most common platform for preparing nucleic acids such as miRNAs for sequencing introduces serious biases. Provided herein are compositions and methods for improved sequencing and miRNA profiling using a set of customized ligation adaptors.

Abstract: A detection-alarm mechanism is provided. The detection-alarm mechanism for a tire includes a sensor, an electronic processing unit, a post-processing unit and a display unit. The sensor includes a substrate disposed in the tire and at least one photoelectronic element fixed to the substrate. If the tire is cracked, light passes through the cracks and reaches the photoelectronic elements to generate signals. The electronic processing unit receives signals from the photoelectronic elements to generate wear information. The post-processing unit is disposed in a vehicle on which the tire is installed and receives wear information from the electronic processing unit. The display unit is disposed in the vehicle for presenting the wear information.

Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.

Abstract: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases.